WORCESTER, Mass., Dec. 15, 2009 (GLOBE NEWSWIRE) -- On December 14, 2009, Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) issued a press release announcing the presentation of interim results from a Phase II efficacy study of a novel immunotherapeutic vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), at the 32nd Annual San Antonio Breast Cancer Symposium (www.sabcs.org).
